XN05, a novel synthesized microtubule inhibitor, exhibits potent activity against human carcinoma cells in vitro

Cancer Letters

Volumn 285, Issue 1, 2009, Pages 13-22

  Wu, Rui ^a   Ding, Wanjing ^a   Liu, Tao ^b   Zhu, Hong ^a   Hu, Yongzhou ^b   Yang, Bo ^a   He, Qiaojun ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Antitumor activity; Apoptosis; Cell cycle arrest; Hepatocellular carcinoma cells; Microtubule inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; COMBRETASTATIN A4; N ACETYL N [4 (4 METHOXYPHENYL) 3 (3,4,5 TRIMETHOXYPHENYL)ISOXASOL 5 YL]ACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROTEIN BCL 2; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; XN 05;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DEPOLYMERIZATION; DRUG STRUCTURE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; MICROTUBULE ASSEMBLY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ACETAMIDES; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASES; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HUMANS; INHIBITORY CONCENTRATION 50; ISOXAZOLES; LIVER NEOPLASMS; MICROTUBULES; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS C-BCL-2; STILBENES; TIME FACTORS; TUBULIN; TUBULIN MODULATORS;

EID: 70349282996     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.04.042     Document Type: Article

References (28)

1. Jordan M.A., and Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4 (2004) 253-265
2. Mollinedo F., and Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 8 (2003) 413-450
3. Pellegrini F., and Budman D.R. Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest. 23 (2005) 264-273
4. Schiff P.B., and Horwitz S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA 77 (1980) 1561-1565
5. Pettit G.R., Singh S.B., Hamel E., Lin C.M., Alberts D.S., and Garia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A4. Experientia 45 (1989) 194-216
6. Chaplin D.J., Pettit G.R., and Hill S.A. Antivascular approaches to solid tumor therapy: evaluation of combretastatin A4 phosphate. Anticancer Res. 19 (1999) 89-195
7. Tron G.C., Pagliai F., Del Grosso E., Genazzani A.A., and Sorba G. Synthesis and cytotoxic evaluation of combretafurazans. J. Med. Chem. 48 (2005) 3260
8. Wang L., Woods K.W., Li Q., Barr K.J., McCroskev R.W., Hannick S.M., Gherke L., Credo R.B., Hui Y.H., Marsh K., Warner R., Lee J.Y., Zielinski-Mozng N., Frost D., Rosenberg S.H., and Sham H.L. Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship pharmacokinetics, and in vivo antitumor activity evaluation. J. Med. Chem. 45 (2002) 1697
9. Sun C.M., Lin L.G., Yu H.J., Cheng C.Y., Tsai Y.C., Chu C.W., Din Y.H., Chau Y.P., and Don M.J. Synthesis and cytotoxic activities of 4,5-diarylisoxazoles. Bioorg. Med. Chem. Lett. 17 (2007) 1078-1159
10. Xue N., Yang X., Wu R., Chen J., He Q., Yang B., Lu X., and Hu Y. Synthesis and biological evaluation of imidazol-2-one derivatives as potential antitumor agents. Bioorg. Med. Chem. 16 (2008) 2550-2557
11. Liou J.-P., Hsu K.-S., Kuo C.-C., Chang C.-Y., and Chang J.-Y. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide(J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule. J. Pharmacol. Exp. Ther. 323 (2007) 398-405
12. Blagosklonny M.V., Schulte T.W., Nguyen P., Mimnaugh E.G., Trepel J., and Neckers L. Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res. 55 (1995) 4623-4626
13. El-Serag H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127 (2004) S27-S34
14. Thomas M.B., and Zhu A.X. Hepatocellular carcinoma: the need for progress. J. Clin. Oncol. 23 (2005) 2892-2899
15. Hui K.M. Human hepatocellular carcinoma: expression profiles-based molecular interpretations and clinical applications. Cancer Lett. 10 (2008) 1-7
16. Attard G., Greystoke A., Kaye S., and De B.J. Update on tubulin-binding agents. Pathol. Biol. 54 (2006) 72-84
17. Chang J.-Y., Chang C.-Y., Kuo C.-C., Chen L.-T., Wein Y.-S., and Kuo Y.-H. Salvinal, a novel microtubule inhibitor isolated from Salvia miltiorrhizae Bunge (Danshen), with antimitotic activity in multidrug-sensitive and -resistant human tumor cells. Mol. Pharmacol. 65 (2004) 77-84
18. Ling Y.-H., Tornos C., and Perez-Soler R. Phosphorylation of Bcl-2 Is a marker of M phase events and not a determinant of apoptosis. J. Biol. Chem. 273 (1998) 18984-18991
19. Larochelle S., Merrick K.A., Terret M.E., Wohlbold L., Barboza N.M., Zhang C., Shokat K.M., Jallepalli P.V., and Fisher R.P. Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol. Cell. 25 (2007) 839-850
20. Tahir S.K., Han E.K., Credo B., Jae H.S., Pietenpol J.A., Scatena C.D., Wu Wong J.R., Frost D., Sham H., and Rosenberq S.H. Hg SC, A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Cancer Res. 61 (2001) 5480-5485
21. Bratton S.B., and Cohen G.M. Death receptors leave a caspase footprint that Smacs of XIAP. Cell Death Differ. 10 (2003) 4-6
22. Deveraux Q.L., and Reed J.C. IAP familyproteins-suppressors of apoptosis. Genes Dev. 13 (1999) 239-252
23. Wilson T.R., McEwan M., McLaughlin K., Le Clorennec C., Allen W.L., Fennell D.A., Johnston P.G., and Lonqley D.B. Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells. Oncogene 28 (2009) 63-72
24. Ndozangue-Touriguine O., Sebbagh M., Mérino D., Micheau O., Bertoglio J., and Bréard J. A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma. Oncogene 27 (2008) 6012-6022
25. Kavallaris M., Tait A.S., Walsh B.J., He L., Horwitz S.B., Norris M.D., and Haber M. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res. 61 (2001) 5803-5809
26. H.D. Homesley, V. Filiaci, S.K. Gibbons, H.J. Long, D. Cella, N.M. Spirtos, R.T. Morris, K. Degeest, R. Lee, A. Montag, A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol (2008) (Epub ahead of print).
27. Jin H., Yang R., Fong S., Totpal K., Lawrence D., Zheng Z., Ross J., Koeppen H., Schwall R., and Ashkenazi A. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res. 64 (2004) 4900-4905
28. Mayer L.D., and Janoff A.S. Optimizing combination chemotherapy by controlling drug ratios. Mol. Interv. 7 (2007) 216-223